133 related articles for article (PubMed ID: 37815216)
1. CAR-T Therapy Targets Extra Domain B of Fibronectin Positive Solid Tumor Cells.
Tang J; Liu N; Zhu Y; Li Y; Zhao X
Immunol Invest; 2023 Nov; 52(8):985-996. PubMed ID: 37815216
[TBL] [Abstract][Full Text] [Related]
2. CAR-T-Cell Therapy for Solid Tumors Positive for Fibronectin Extra Domain B.
Zhang Z; Liu C; Yang Z; Yin H
Cells; 2022 Sep; 11(18):. PubMed ID: 36139437
[TBL] [Abstract][Full Text] [Related]
3. Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin.
Zhang Z; Liu C; Wang M; Sun R; Yang Z; Hua Z; Wu Y; Wu M; Wang H; Qiu W; Yin H; Yang M
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586774
[TBL] [Abstract][Full Text] [Related]
4. Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin.
Wagner J; Wickman E; Shaw TI; Anido AA; Langfitt D; Zhang J; Porter SN; Pruett-Miller SM; Tillman H; Krenciute G; Gottschalk S
Cancer Immunol Res; 2021 Mar; 9(3):279-290. PubMed ID: 33355188
[TBL] [Abstract][Full Text] [Related]
5. Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma.
Saw PE; Xu X; Kang BR; Lee J; Lee YS; Kim C; Kim H; Kang SH; Na YJ; Moon HJ; Kim JH; Park YK; Yoon W; Kim JH; Kwon TH; Choi C; Jon S; Chong K
Theranostics; 2021; 11(2):941-957. PubMed ID: 33391514
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Assessment of the Effectiveness of Magnetic Resonance Molecular Imaging of Extradomain-B Fibronectin for Detection and Characterization of Oral Cancer.
Hall RC; Ayat NR; Qiao PL; Vaidya AM; Ma D; Aminoshariae A; Stojanov I; Lu ZR
Mol Imaging Biol; 2020 Dec; 22(6):1532-1542. PubMed ID: 32789648
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin.
Vaidya A; Ayat N; Buford M; Wang H; Shankardass A; Zhao Y; Gilmore H; Wang Z; Lu ZR
Theranostics; 2020; 10(24):11127-11143. PubMed ID: 33042274
[TBL] [Abstract][Full Text] [Related]
8. MRI of breast tumor initiating cells using the extra domain-B of fibronectin targeting nanoparticles.
Sun Y; Kim HS; Park J; Li M; Tian L; Choi Y; Choi BI; Jon S; Moon WK
Theranostics; 2014; 4(8):845-57. PubMed ID: 24955145
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance molecular imaging of extradomain B fibronectin enables detection of pancreatic ductal adenocarcinoma metastasis.
Qiao PL; Gargesha M; Liu Y; Laney VEA; Hall RC; Vaidya AM; Gilmore H; Gawelek K; Scott BB; Roy D; Wilson DL; Lu ZR
Magn Reson Imaging; 2022 Feb; 86():37-45. PubMed ID: 34801672
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles targeting extra domain B of fibronectin-specific to the atherosclerotic lesion types III, IV, and V-enhance plaque detection and cargo delivery.
Yu M; Ortega CA; Si K; Molinaro R; Schoen FJ; Leitao RFC; Xu X; Mahmoudi M; Ahn S; Liu J; Saw PE; Lee IH; Brayner MMB; Lotfi A; Shi J; Libby P; Jon S; Farokhzad OC
Theranostics; 2018; 8(21):6008-6024. PubMed ID: 30613278
[TBL] [Abstract][Full Text] [Related]
11. Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade.
Hooper AT; Marquette K; Chang CB; Golas J; Jain S; Lam MH; Guffroy M; Leal M; Falahatpisheh H; Mathur D; Chen T; Kelleher K; Khandke K; Muszynska E; Loganzo F; Rosfjord E; Lucas J; Kan Z; Subramanyam C; O'Donnell C; Neri D; Gerber HP; May C; Sapra P
Mol Cancer Ther; 2022 Sep; 21(9):1462-1472. PubMed ID: 35793468
[TBL] [Abstract][Full Text] [Related]
12. A serologically assessed neo-epitope biomarker of cellular fibronectin degradation is related to pulmonary fibrosis.
Hansen AH; Breisnes HW; Prior TS; Hilberg O; Rasmussen DGK; Genovese F; Lukassen MV; Svensson B; Langholm LL; Manon-Jensen T; Karsdal MA; Leeming DJ; Bendstrup E; Sand JMB
Clin Biochem; 2023 Aug; 118():110599. PubMed ID: 37343745
[TBL] [Abstract][Full Text] [Related]
13. EDB-FN targeted probes for the surgical navigation, radionuclide imaging, and therapy of thyroid cancer.
Li R; He H; Li X; Zheng X; Li Z; Zhang H; Ye J; Zhang W; Yu C; Feng G; Fan W
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2100-2113. PubMed ID: 36807768
[TBL] [Abstract][Full Text] [Related]
14. EDB fibronectin and angiogenesis -- a novel mechanistic pathway.
Khan ZA; Chan BM; Uniyal S; Barbin YP; Farhangkhoee H; Chen S; Chakrabarti S
Angiogenesis; 2005; 8(3):183-96. PubMed ID: 16308732
[TBL] [Abstract][Full Text] [Related]
15. [Study on construction of c-Met specific CAR-T cells and its killing effect on non-small cell lung carcinoma].
Min JT; Zhang L; Long CR; Fan HL; Li ZZ
Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):322-329. PubMed ID: 37078213
[No Abstract] [Full Text] [Related]
16. EDB-FN Targeted Peptide-Drug Conjugates for Use against Prostate Cancer.
Park SE; Shamloo K; Kristedja TA; Darwish S; Bisoffi M; Parang K; Tiwari RK
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31277465
[TBL] [Abstract][Full Text] [Related]
17. A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B.
Balza E; Sassi F; Ventura E; Parodi A; Fossati S; Blalock W; Carnemolla B; Castellani P; Zardi L; Borsi L
Int J Cancer; 2009 Aug; 125(4):751-8. PubMed ID: 19479996
[TBL] [Abstract][Full Text] [Related]
18. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
19. CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors.
Dragon AC; Beermann LM; Umland M; Bonifacius A; Malinconico C; Ruhl L; Kehler P; Gellert J; Weiß L; Mayer-Hain S; Zimmermann K; Riese S; Thol F; Beutel G; Maecker-Kolhoff B; Yamamoto F; Blasczyk R; Schambach A; Hust M; Hudecek M; Eiz-Vesper B
Front Immunol; 2023; 14():1219165. PubMed ID: 37915564
[TBL] [Abstract][Full Text] [Related]
20. CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models.
Timpanaro A; Piccand C; Dzhumashev D; Anton-Joseph S; Robbi A; Moser J; Rössler J; Bernasconi M
J Exp Clin Cancer Res; 2023 Nov; 42(1):293. PubMed ID: 37924157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]